31E9
31E9
规格:
货期:
编号:TS212909
品牌:Testobio
| 产品名称： | 31E9 |
|---|---|
| 商品货号： | TS212909 |
| Organism： | human (B cell); human (leukemia) |
| Cell Type： | hybridoma: T lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Allergen |
| Applications： | The cells produce antigen specific GIF. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells). |
| Clinical Data： | Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells). |
| Genes Expressed： | Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF) |
| Cellular Products： | Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF) |
| Comments： | Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells). The cells produce antigen specific GIF. Cryj-1 is a 40000 dalton glycoprotein that constitutes the major allergen in Japanese cedar pollen. |
| Complete Growth Medium： | The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell culture grade water. To make the complete growth medium, add the following components to the base medium: |
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Name of Depositor： | La Jolla Institute for Allergy and Immunology |
| U.S. Patent Number： | |
| References： | Ishizaka K. Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. US Patent 5,565,338 dated Oct 15 1996 Ishizaka K. Antigen-specific human glycosylation inhibiting factor. US Patent 5,723,582 dated Mar 3 1998 |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
31E9
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | 31E9 |
|---|---|
| 商品货号： | TS212909 |
| Organism： | human (B cell); human (leukemia) |
| Cell Type： | hybridoma: T lymphocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | Allergen |
| Applications： | The cells produce antigen specific GIF. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells). |
| Clinical Data： | Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells). |
| Genes Expressed： | Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF) |
| Cellular Products： | Japanese cedar pollen cryj-1 specific human glycosylation inhibiting factor (GIF) |
| Comments： | Peripheral blood T cells from a patient allergic to Japanese cedar pollen were fused with BUC cells (HPRT - derivative of CEM cells). The cells produce antigen specific GIF. Cryj-1 is a 40000 dalton glycoprotein that constitutes the major allergen in Japanese cedar pollen. |
| Complete Growth Medium： | The base medium for this cell line is ATCC Hybri-Care Medium, Catalog No. 46-X. Hybri-Care Medium is supplied as a powder and should be reconstituted in 1 L cell culture grade water. To make the complete growth medium, add the following components to the base medium: |
| Subculturing： | Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Name of Depositor： | La Jolla Institute for Allergy and Immunology |
| U.S. Patent Number： | |
| References： | Ishizaka K. Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor. US Patent 5,565,338 dated Oct 15 1996 Ishizaka K. Antigen-specific human glycosylation inhibiting factor. US Patent 5,723,582 dated Mar 3 1998 |
